Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

41.95
+0.14880.36%
Post-market: 41.950.00000.00%19:30 EDT
Volume:271
Turnover:11.43K
Market Cap:31.47M
PE:- -
High:42.09
Open:42.03
Low:41.95
Close:41.81
52wk High:43.51
52wk Low:29.80
Shares:750.00K
Float Shares:750.00K
Volume Ratio:0.31
T/O Rate:0.04%
Dividend:0.14
Dividend Rate:0.34%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open

Simply Wall St.
·
Aug 04

AI-Driven Lung Cancer Screening Advances Precision Medicine, Boosting Opportunities for TH MEDICAL-B (02697)

Stock News
·
Aug 04

Asymchem shares surge 5% on plan to inject 1.05 billion yuan into biotech subsidiary

Stock News
·
Aug 04

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176

Reuters
·
Aug 04

ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)

TIPRANKS
·
Aug 04

ClearPoint Neuro Q2 Revenue Rises 18% but Misses Estimates

Reuters
·
Aug 04

GeneDx Q2 Revenue Beats Analyst Estimates

Reuters
·
Aug 04

Krystal Biotech Down Nearly 12%, on Pace for Largest Percent Decrease Since August 2025

Dow Jones
·
Aug 04

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 04

Analysts Conflicted on These Healthcare Names: Guardant Health (GH) and Cardinal Health (CAH)

TIPRANKS
·
Aug 03

Krystal Biotech Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Design Therapeutics Q2 Net Loss Narrower than Expected

Reuters
·
Aug 03

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

Reuters
·
Aug 03

Krystal Biotech Q2 Revenue Rises on Vyjuvek Strength

Reuters
·
Aug 03

Krystal Biotech Shares Down 5.8% Premarket After Q2 Results

THOMSON REUTERS
·
Aug 03

Krystal Biotech Q2 Net Income Rises 43% to $54.8 Million; Revenue Climbs 24% to $119.2 Million

Reuters
·
Aug 03

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

THOMSON REUTERS
·
Aug 03

Krystal Biotech - Sees FY 2026 Non-Gaap R&D and SG&a Expense $175 Mln-$195 Mln

THOMSON REUTERS
·
Aug 03

Krystal Biotech Q2 Product Revenue USD 119.222 Million

THOMSON REUTERS
·
Aug 03

Guardant Health Shares Climb Following Outlook Raise

Dow Jones
·
Jul 31